key: cord-1004945-kkf0zj5v
authors: Zangrillo, Alberto; Belletti, Alessandro; Palumbo, Diego; Calvi, Maria Rosa; Guzzo, Francesca; Fominskiy, Evgeny V.; Ortalda, Alessandro; Nardelli, Pasquale; Ripa, Marco; Redaelli, Martina Baiardo; Borghi, Giovanni; Landoni, Giovanni; D'Amico, Filippo; Marmiere, Marilena; Righetti, Beatrice; Rocchi, Margherita; Saracino, Marco; Tresoldi, Moreno; Dagna, Lorenzo; De Cobelli, Francesco
title: One-year multidisciplinary follow-up of COVID-19 patients requiring invasive mechanical ventilation
date: 2021-11-27
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.11.032
sha: 672187e25c4fa2a559ebca81ee62fe8ea7700676
doc_id: 1004945
cord_uid: kkf0zj5v

Objective Patients with COVID-19 frequently develop acute respiratory distress syndrome (ARDS) requiring intensive care unit (ICU) admission. Data on long-term survival of these patients are lacking. We investigated 1-year survival, quality of life and functional recovery of COVID-19 ARDS patients requiring invasive mechanical ventilation Design Prospective observational study Setting Tertiary-care university hospital Participants All COVID-19 ARDS patients receiving invasive mechanical ventilation and discharged alive from hospital Interventions Patients were contacted by phone after 1-year. Functional, cognitive, and psychological outcomes were explored through a questionnaire and assessed using validated scales. Patients were offered the possibility to undergo a follow-up chest CT scan. Measurements and Main Results The study included all adult (age ≥ 18 years) patients with COVID-19-related ARDS admitted to an ICU of our institution between February 25th, 2020 - April 27th, 2020), who received at least one day of invasive mechanical ventilation (IMV). Of 116 patients who received IMV, 61 (52.6%) survived to hospital discharge. These survivors were assessed one year after discharge and 56 completed a battery of tests of cognition, activities of daily living and interaction with family members. They had overall good functional recovery, with >80% reporting good recovery and no difficulties in usual activities. A total of 52 (93%) of patients had no dyspnea at rest. Severe anxiety/depression was reported by five (8.9%) of patients. Comparing 2-months and 1-year data, we observed the most significant improvements in the areas of working status and exertional dyspnea. One-year Chest CT scans were available for 36 patients: fibrotic-like changes were present in four patients. Conclusions All patients who survived the acute phase of the COVID-19 disease and were discharged from the hospital were alive at the 1-year follow up and the vast majority of them had good overall recovery and quality of life. Study Registration ClinicalTrials.gov NCT04318366

In the first months of 2020, the Coronavirus Disease 2019 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spread all over the world becoming pandemic, and causing a surge of intensive care unit (ICU) admissions due to severe respiratory failure and acute respiratory distress syndrome (ARDS). [1] [2] [3] [4] Previous studies performed in non-COVID-19 ARDS patients showed that ARDS is frequently associated with long-term functional, psychological and cognitive impairment and reduced quality of life in ICU survivors. [5] [6] [7] [8] A similar pattern has been described for other respiratory coronaviruses infections (SARS-CoV-1 and Middle East Respiratory Syndrome [MERS] ) as well as for the general ICU population. [9] [10] [11] [12] [13] [14] Short-term mortality rate for COVID-19-related ARDS requiring invasive mechanical ventilation is around 50 %, 3, 15 . However, data on long-term mortality and quality of life in this setting are scarce. 16, 17 In addition, previous studies showed conflicting data on mid-term recovery, with some studies suggesting an overall reduced quality of life and poor functional recovery 18, 19 , while other reported an overall good quality of life and better functional recovery as compared with non-COVID-19-related ARDS. 20 Our group recently published the two months follow-up data of our cohort of invasively ventilated, COVID-19 ICU survivors. 20 Accordingly, we have now performed a 1-year follow-up study of the same cohort to investigate long-term mortality, quality of life, functional and psychological recovery of our patients, as well as computed tomography (CT) characteristics of the lungs.

This study is part of the COVID-BioB study, a prospective observational study performed at ***BLINDED***, a 1,350-bed teaching hospital in Italy. The study was approved by the hospital Ethics Committee (protocol No. 34/int/2020) and was registered on ClinicalTrials.gov (NCT04318366). 21, 22 Inclusion and exclusion criteria Details on inclusion and exclusion criteria of our follow-up studies have been previously published. 20, 21 Briefly, this study included all adult (age ≥ 18 years) patients with COVID-19-related ARDS admitted to an ICU of our institution between February 25 th , 2020 -April 27 th , 2020 (first Italian pandemic wave 23see Supplementary Figure 1 ), who received at least one day of invasive mechanical ventilation (IMV). Of 116 patients who received IMV during the study period, 61 (52.6%) survived to hospital discharge. These survivors were contacted one year after discharge and were given a battery of tests of cognition, activities of daily living and interaction with family members (details on data collection are provided below).

Details on hospital organization and patients management in ICU and general wards have been previously published. 4, [20] [21] [22] [24] [25] [26] Invasive mechanical ventilation, fluid and pharmacological management of patients were performed according to international guidelines and experts recommendations. [27] [28] [29] [30] [31] Briefly, we aimed for a tidal volume of 6-8 mL/kg of ideal body weight, a driving pressure of ≤ 15 cmH 2 O, and a pH > 7.25. Positive end-expiratory pressure (PEEP) was initially set according to the ARDSnet low PEEP/high FiO 2 table, and then individualized according to respiratory system mechanics, hemodynamics and oxygenation. During the first days of ICU stay, we aimed for a slightly negative fluid balance as tolerated by hemodynamics and end-organ function. Rescue treatments including prone positioning, use of neuromuscular blockade, inhaled nitric oxide, and extracorporeal membrane oxygenation were used as suggested by international guidelines on ARDS management available at that time. 27, 31 Antivirals, adjuvants and immunosuppressants (e.g. steroids) were administered according to clinical judgement and evidence available at that time. 21

Study methodology has been previously described. 20, 21 For this specific 1-year follow-up study, the primary outcome was 1-year survival. We chose survival as primary outcome as this is a strong, clinically relevant outcome and there are no data on 1-year survival of patients with COVID-19-related ARDS who required invasive mechanical ventilation. All other items addressed by the follow-up questionnaire were secondary outcomes.

Baseline demographic and ICU treatment data were collected. For each patient we had at least one telephone number, either belonging to the patient or to a caregiver. The discharged patients were contacted by phone by a trained investigator, and data were progressively recorded in a dedicated database during the phone interview. Firstly, we asked the patient to confirm his/her identity and date of birth, and then we asked further contact details and information about: dysosmia and dysgeusia, either before the onset of the disease and after discharge;

discrimination that they (or their families) may have endured because of the disease, including denied access to non-urgent care. After that, we administered a telephone assessment composed of various items, in order to explore multidimensional outcomes. The questionnaire was the same used for the 2-months follow-up, 20 and items are described in details below and in the Supplementary Appendix. Finally, a chest CT scan was offered to all patients. Data were progressively recorded in a dedicated database during the phone interview.

Multidimensional outcomes were evaluated following our previous protocol. 20 We explored physical recovery and disability via the Glasgow Outcome Scale extended (GOSe), 32 

All CT examinations were performed on a 64-row multidetector CT scanner (SOMATOM Definition Flash Dual Source CT, Siemens Healthcare). CT protocol included an unenhanced, breath-hold axial scans of the thorax (from lung apex to the lowest hemidiaphragm); if any concern existed about air trapping, 47 an expiratory scan was also performed.

Two experienced radiologists, both blinded to patients' eventual symptoms, independently reviewed all CT images for fibrotic-like changes (honeycombing, reticulation and traction bronchiectasis); 47 differences in assessment were resolved with consensus.

Imaging post processing was carried out with commercially available software (Intellispace version 8.0, Philips Medical Systems, Chronic Obstructive Pulmonary Disease tool); after automated identification of pulmonary lobes on lung parenchyma windowed slices, the software estimated total lung volume (expressed as cubic centimetre [cc]) and also differentiated diverse areas of lung parenchyma based on Hounsfield Unit (HU) thresholds. To quantify and differentiate between normal and pathologic lung parenchyma, a -740 HU threshold was set: areas with higher-density values were considered pathologic (residual lung damage, expressed as percentage of the whole lungs volume). 48 One-year follow-up imaging was compared to chest CT scans of the same patients acquired three months after ICU discharge. Accordingly, any change in the burden of residual lung damage was noted.

Statistical analysis was performed using Stata 16 We compared baseline characteristics and treatment data patients with a good overall recovery (defined as Glasgow Outcome Scale extended of 7 or greater) and patients with persistent disability.

Data were compared among the groups using Fisher exact tests or Wilcoxon rank-sum tests. We included variables with a p-value of less than 0.05 at univariate analysis in a multiple logistic regression model to predict good 1-year functional outcome. Collinearity and overfitting were assessed using a stepwise regression model and Pearson correlation test. In the multiple logistic regression analyses, we expressed clinical factors or potential confounding variables as odds ratio (OR) with 95% confidence interval (CI). A p-value < 0.05 was considered significant.

A convenience sample was chosen for this preliminary observational study. A post-hoc power calculation considering a 1-year post-ICU-discharge mortality for ARDS patients of 10% 8 and an alpha of 0.05 showed that the study has a power of 80.5%.

Overall, a total of 116 COVID-19-related ARDS patients were admitted to an ICU at our institution and received invasive mechanical ventilation ( Figure 1 ). Of these, 61 patients ( Table 1 , while data on specific medical therapies received are presented in Supplementary Table 1 . Patients were prevalently males (89%) and were 56 ± 11.9 years old.

The overall quality of life assessed through the EQ-5D-3L test showed that the vast majority of patients had no difficulty in walking (82%), self-care (95%), or usual activities (84%). A total of five patients (8.9%) reported severe anxiety/depression (Table 2) .

At 1-year follow-up, psychological tests confirmed low rates of anxiety, depression, PTSD, insomnia and cognitive impairment ( Table 2) .

Six patients (11% of the total number and 16% of those able to work at baseline) reported not being able to work due disease-dependent reason ( Table 2) .

A total of 45/56 patients (80.3%) reported good recovery as defined by the GOSe. Similarly, 93%

of patients had no dyspnea at rest, while 16/56 (28.5%) reported exertional dyspnea (ranging from "light" to "very strong"). A total of 50 patients (89%) reported to walk independently anywhere.

The MNA-SF showed that 19/56 patients (33.9%) were malnourished or at risk for malnutrition ( Table 3) .

Episodes of reported personal or family discrimination due to their COVID-19 illness were reported by four (7.1%) and four (7.1%) of patients, respectively ( Table 2) .

Alterations in smell and taste were present before ICU admission in five (8.9%) and five (8.9%) patients, respectively, and persisted after hospital discharge in four (7.1%) and four (7.1%) patients (Table 2) . Overall recovery expressed as GOSe was not different among those who were hospitalized for less two months (N=41) as compared with those hospitalized longer than two months (N=13) (median GOSe 8 (7-8) versus 8 (7) (8) , respectively, p = 0.61, with data available for 54 patients).

A total of 36 patients (64.3%) underwent one-year follow-up chest CT scan. Of these, 29/36

(80.5%) already had a previous follow-up chest CT scan three months after ICU discharge, and were subsequently enrolled in this analysis.

Collectively, follow-up studies investigating short-term recovery after critical COVID-19 showed a significant burden of functional limitations and psychological sequelae in ICU survivors, but with gradual improvement over the period from discharge to six months. 50, 52 In the largest study, Morin et al. assessed four-months respiratory, cognitive, and functional outcomes in 478 COVID-19 patients, including 142 who had been admitted to the ICU and 73 intubated patients. 19 In their study, the Authors used different scales but dyspnea was reported in 34% of intubated patients, somewhat higher than our 28% of exertional dyspnea. Similarly to our study, anxiety or depression were present in about 25% of patients, and fibrotic changes were observed in 20% of patients. Unfortunately, the Authors did not present information on post-ICU discharge survival, although the overall mortality after hospitalization was 12% in their cohort

Other studies showed a relatively low post-discharge mortality, similar to our study, with variable rates of radiological, functional and psychological recovery. 18, 50, 51 Interestingly, in contrast to previous publications, 8, 51 we found that age, duration of ICU stay and mechanical ventilation were not independently associated with 1-year outcome, while we identified baseline comorbidities as a key risk factor. However, these findings may be simply due to different definitions of good outcome and different length of follow-ups.

However, heterogeneity of previous studies in terms of enrolled patient population (hospitalized/non hospitalized, critically ill/non critically ill, ventilated/non ventilated patients), the different time point of the follow up (the majority of the studies had shorter follow up), and the different metrics adopted by researchers to assess the outcomes, makes our findings only partially comparable with previous literature.

Comparison with non-COVID-19-related ARDS is difficult due to frequent use of different scale to assess quality of life and recovery. Interestingly, we observed a higher post-discharge survival as compared with non-COVID-19-related ARDS, where post-ICU mortality has been reported to be as high as 11%. 8 However, available studies collectively showed reduced quality of life, functional recovery, and several psychological sequelae, with a relatively high prevalence of post-traumatic stress disorder. 5, 7, [53] [54] [55] Our data, together with data from other studies, suggest that recovery from critical COVID-19-related ARDS is somewhat better than for non-COVID-19-related ARDS, although studies providing direct comparison between these two populations are lacking.

Interestingly, on that note, we observed a median residual lung damage at 1-year follow-up of 7.6%, slightly lower when compared with previous reports concerning non-COVID-19-related ARDS, reporting a residual lung damage involving 10 to 25% of lung parenchyma. 56

Our study, together with data from literature, suggest that, in COVID-19-related ARDS patients, mortality after ICU discharge is low and long-term recovery is overall good. In particular, clinical findings are consistent with radiological findings obtained through follow-up chest CT scans.

Therefore, our data underline that clinicians caring for COVID-19 patients, and in particular for those admitted to an ICU, should be reassured that patients surviving the acute phase will have a good functional recovery after one year. Of course, our data should be interpreted considering that ICU mortality of COVID-19-related ARDS patients is approximately 50%. 15 Furthermore, our study suggests that post-ICU multidisciplinary follow-up for critically ill patients may have an important role for long-term outcomes. 14, 57 The 60 Inside this complex disease, we found a relatively low prevalence of neurologic impairment at 1-year as compared with previous literature and studies with shorter follow-up. 61 Indeed, among COVID-19 survivors, anxiety, depression, sleep disturbance and PTSD were reported up to 30-40%. 59 , although prevalence of these disturbances is highly variable across studies. 62 It is possible that the relatively young age of our patients and the prevalence of males, 63 led to better recovery from critical illness. Furthermore, symptoms of post-intensive care syndrome have been shown to improve over time 14 , and is possible that our dedicated post-COVID-19 followup clinic helped in subsequent recovery. 57, 64, 65 Notably, in a 6-month post discharge assessment of 63 Indeed, female sex was confirmed in several publication to be a risk factor for long-term psychologic/psychiatric sequalae, 62 and several studies confirmed improvement of symptoms over time also after COVID-19-related ARDS. 62 Notably, our data were collected at the beginning of the COVID-19 pandemic, thus before delta variant became prevalent. In particular, the first case of delta variant in Italy was registered in April 2021, one year after the admission in the ICU of our last patient. Our data may therefore not apply to delta variant patients.

Our study confirms radiological data from previous studies, which reported unexpected low prevalence of fibrotic-like changes at short-term follow-up, 19, 50, 66 and also provides new insights suggesting reversal of these changes and further lung healing after one year. A possible explanation could lie in the previously proposed virus-induced lung frailty, which is thought to be a main contributor for the high incidence of barotrauma in COVID-19 patients. 67, 68 In this prospective, the honeycombing CT pattern, when present, could represent a subpleural cluster of small pneumatoceles rather than cystic air spaces resulting from irreversible lobular disruption.

Furthermore, residual lung damage does not necessarily correspond to lung fibrosis, which instead has a strict radiological definition. 47 Finally, a relevant proportion of our patients received hydroxychloroquine as adjuvant antiviral therapy. Notably, following publication of several randomized trials showing negative results, 69 use of hydroxychloroquine as treatment for COVID-19 greatly decreased and is no longer recommended. Although we cannot exclude that use of the drug contributed to the good long-term outcome, this seems unlikely given the negative results of major randomized on its use.

This is the first study presenting clinical and radiological 1-year follow-up data for patients with COVID-19-related ARDS . A strength of our study is the absence of "lost-to-follow-up" patients and the almost complete questionnaire follow-up. Furthermore, we employed several previously validated scales to assess functional, psychological and cognitive outcomes. Finally, the presence of quantitative radiological data represents major strength of the present study

The study is limited by its single-center design, by the small sample size, and by absence of a control, non-COVID-19-related ARDS group and non-invasively ventilated COVID-19 patients.

However, obtaining a control group of a comparable during the same time this was almost impossible due to the overwhelming number of COVID-19 cases. The present study focused only on patients who received invasive mechanical ventilation (i.e. the most severely ill patients) while the long term outcome of patients treated with non-invasive ventilation is currently under investigation. 24, 70, 71 Patients included in our study were relatively young, prevalently male, with normal BMI and few comorbidities. Older patients with greater burden of comorbidities were less likely to be admitted to ICU during pandemic crisis 24, 71 , and had higher risk of death. Therefore, our data may suffer from selection, gender and survival bias. 3, 15 However, age range of patients admitted to our ICUs is comparable to that of patients admitted to ICUs in the whole Lombardy region during the same period, 3, 15 and a male prevalence of our ICU and hospitalized patients was already known. 72 We did not collect data on long-term occurrence rate of cardiovascular and thrombotic events, or long-term organ function (e.g. renal function or pulmonary function tests). However, investigation of these outcomes was not among the objectives of this study and is currently subject of separate investigations. 73 The study is not randomized, so we can't determine whether referral of patients to our post-COVID follow-up clinic 57 has influenced long-term outcome.

Future studies should confirm in a larger sample size our findings of a low post-discharge mortality and good functional and radiological recovery following COVID-19-related ARDS. In addition, the role of post-ICU follow-up clinics, as well as multidisciplinary long-term management protocols should be assessed and defined.

Finally, future studies should further define the correlation between pathogenesis of COVID-19 lung damage, acute-phase treatments, and long-term lung fibrosis.

Our study suggests that, among ICU patients with COVID-19-related ARDS who required invasive mechanical ventilation and were discharged alive from hospital (approximately 50% of ICU COVID-19-related ARDS patients receiving invasive ventilation), 1-year survival is high. Table 4 -Quantitative assessment of residual lung damage and total lung volume at both time points (three months and one year follow-up).

Adaptations and Lessons in the Province of Bergamo

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast during an Emergency Response

Baseline Characteristics and Outcomes of 1591

Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Fast reshaping of intensive care unit facilities in a large metropolitan

Long-term outcome after the acute respiratory distress syndrome: Different from general critical illness?

Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers

Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome

Functional Disability 5 Years after Acute Respiratory Distress Syndrome

Long-term clinical outcomes in survivors of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference

The impact of disability in survivors of critical illness

Recovery after critical illness: Putting the puzzle together-a consensus of 29

Health-related quality of life and physical recovery after a critical illness: A multi-centre randomised controlled trial of a home-based physical rehabilitation program

Long-term Quality of Life After Intensive Care Unit Admission (a Single-Center Observational Study)

Risk Factors Associated with Mortality among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy

Long-term complications of COVID-19 in ICU survivors: what do we know? Minerva Anestesiol

One-Year Functional, Cognitive, and Psychological Outcomes Following the Use of Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019: A Prospective Study

Quality of life, functional status, and persistent symptoms after intensive care of COVID-19 patients

Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19

Two months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Biobanking for COVID-19 research

Pneumothorax/pneumomediastinum in nonintubated COVID-19 patients: Differences between first and second Italian pandemic wave

Continuous positive airway pressure and pronation outside the intensive care unit in COVID 19 ARDS

Respiratory Parameters in Patients with COVID-19 after Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit

Feasibility and safety of angiotensin II administration in general ward patients during COVID-19 pandemic: a case series

An official American Thoracic Society/European Society of intensive care medicine/society of critical care medicine clinical practice guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome

Fluid administration and monitoring in ARDS: which management?

Neuromuscular blockade in patients with ARDS: a rapid practice guideline

Management of critically ill patients with COVID-19: suggestions and instructions from the coordination of intensive care units of Lombardy

Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)

Structured interviews for the glasgow outcome scale and the extended glasgow outcome scale: Guidelines for their use

Disability after severe head injury: Observations on the use of the Glasgow Outcome Scale

Clinical gait assessment in the neurologically impaired. Reliability and meaningfulness

Psychophysical bases of perceived exertion

Rating of Perceived Exertion for Quantification of the Intensity of Resistance Exercise

Validation of the Mini Nutritional Assessment shortform (MNA®-SF): A practical tool for identification of nutritional status

EuroQol -a new facility for the measurement of health-related quality of life. Health Policy

Italian population-based values of EQ-5D health states. Value Heal

Psychometric evaluation of the Hospital Anxiety and Depression Scale 3 months after acute lung injury

The Hospital Anxiety and Depression Scale

The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): Development and Initial Psychometric Evaluation

the English and French versions of the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)

Comparative validation of three screening instruments for posttraumatic stress disorder after intensive care

The insomnia severity index: Psychometric indicators to detect insomnia cases and evaluate treatment response

The ITEL-MMSE: An Italian telephone version of the Mini-Mental State Examination

Fleischner Society: Glossary of terms for thoracic imaging

Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach

Recovery after critical illness in COVID-19 ICU survivors

Quality of life of COVID-19 critically ill survivors after ICU discharge: 90 days follow-up

Functional status of mechanically ventilated COVID-19 survivors at ICU and hospital discharge

One-year resource utilisation, costs and quality of life in patients with acute respiratory distress syndrome (ARDS): Secondary analysis of a randomised controlled trial

Six-month quality-of-life and functional status of acute respiratory distress syndrome survivors compared to patients at risk: A population-based study

Cooccurrence of and remission from general anxiety, depression, and posttraumatic stress disorder symptoms after acute lung injury: A 2-year longitudinal study

What's Next After ARDS: Long-Term Outcomes

Post-COVID-19 follow-up clinic: Depicting chronicity of a new disease

Long COVID" as a Disability Under the ADA, Section | HHS

Post-acute COVID-19 syndrome

Long COVID: to investigate immunological mechanisms and sex/gender related aspects as fundamental steps for a tailored therapy

Resilience in Survivors of Critical Illness in the Context of the Survivors' Experience and Recovery

Psychiatric and neuropsychiatric sequelae of COVID-19 -A systematic review

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study

Physical and psychological sequelae at three months after acute illness in COVID-19 survivors

Comprehensive health assessment three months after recovery from acute COVID-19

Barotrauma in Coronavirus Disease 2019 Patients Undergoing Invasive Mechanical Ventilation:A Systematic Literature Review

mechanically ventilated COVID-19 patients

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

6-Month Respiratory Outcomes and Exercise Capacity of COVID-19 Acute Respiratory Failure Patients Treated With CPAP

Outcomes of non-invasive ventilation as the ceiling of treatment in patients with COVID-19

Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity

Residual lung damage following ARDS in COVID-19 ICU survivors

 13 .7 (9.5 -20.8) 6.6 (4.7 -11.6) 7.0 (3.1 -11.8) Left lower lobe 23 .1 (10.7 -30.4) 8.5 (5.9 -13.4) 12.5 (4.1 -18,1)